Literature DB >> 25531791

A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep.

Louise Organ1, Barbara Bacci, Emmanuel Koumoundouros, Garry Barcham, Wayne Kimpton, Cameron J Nowell, Chrishan Samuel, Ken Snibson.   

Abstract

BACKGROUND: Idiopathic Pulmonary fibrosis (IPF) is a fatal respiratory disease, characterized by a progressive fibrosis and worsening lung function. While the outcomes of recent clinical trials have resulted in therapies to slow the progression of the disease, there is still a need to develop alternative therapies, which are able to prevent fibrosis. AIM: This study uses a segmental lung infusion of bleomycin (BLM) to investigate pulmonary fibrosis in a physiologically relevant large animal species.
METHODS: Two separate lung segments in eight sheep received two fortnightly challenges of either 3U or 30U BLM per segment, and a third segment received saline (control). Lung function was assessed using a wedged-bronchoscope procedure. Bronchoalveolar lavage fluid and lung tissue were assessed for inflammation, fibrosis and collagen content two weeks after the final dose of BLM.
RESULTS: Instillation of both BLM doses resulted in prominent fibrosis in the treated lobes. More diffuse fibrosis and loss of alveolar airspace was observed in high-dose BLM-treated segments, while multifocal fibrosis was seen in low-dose BLM-treated segments. Extensive and disorganised collagen deposition occurred in the BLM-treated lobes, compared to controls. Significant loss of lung compliance was also observed in the BLM-treated lobes, which did not occur in controls.
CONCLUSIONS: Fibrosis comparable to IPF was induced into isolated lung segments, without compromising the respiratory functioning of the animal. This model may have potential for investigating novel therapies for IPF by allowing direct comparison of multiple treatments with internal controls, and sampling and drug delivery that are clinically relevant.

Entities:  

Keywords:  bleomycin; lung compliance; pulmonary fibrosis; segmental challenge; sheep

Mesh:

Substances:

Year:  2014        PMID: 25531791     DOI: 10.3109/01902148.2014.985806

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  8 in total

1.  A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice.

Authors:  Francesca Ruscitti; Francesca Ravanetti; Gaetano Donofrio; Yanto Ridwan; Paula van Heijningen; Jeroen Essers; Gino Villetti; Antonio Cacchioli; Wim Vos; Franco Fabio Stellari
Journal:  J Vis Exp       Date:  2018-04-13       Impact factor: 1.355

Review 2.  Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics.

Authors:  Shuchan Li; Jianrong Shi; Huifang Tang
Journal:  Cell Biol Toxicol       Date:  2021-11-05       Impact factor: 6.819

Review 3.  Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis.

Authors:  Jun Tashiro; Gustavo A Rubio; Andrew H Limper; Kurt Williams; Sharon J Elliot; Ioanna Ninou; Vassilis Aidinis; Argyrios Tzouvelekis; Marilyn K Glassberg
Journal:  Front Med (Lausanne)       Date:  2017-07-28

4.  Heterologous Matrix Metalloproteinase Gene Promoter Activity Allows In Vivo Real-time Imaging of Bleomycin-Induced Lung Fibrosis in Transiently Transgenized Mice.

Authors:  Fabio Franco Stellari; Francesca Ruscitti; Daniela Pompilio; Francesca Ravanetti; Giulia Tebaldi; Francesca Macchi; Andrea Elizabeth Verna; Gino Villetti; Gaetano Donofrio
Journal:  Front Immunol       Date:  2017-03-01       Impact factor: 7.561

5.  Increased Levels of ER Stress and Apoptosis in a Sheep Model for Pulmonary Fibrosis Are Alleviated by In Vivo Blockade of the KCa3.1 Ion Channel.

Authors:  Udari E Perera; Louise Organ; Sasika N V Dewage; Habtamu B Derseh; Andrew Stent; Kenneth J Snibson
Journal:  Can Respir J       Date:  2021-03-19       Impact factor: 2.409

6.  The efficacy and safety of pinocembrin in a sheep model of bleomycin-induced pulmonary fibrosis.

Authors:  Habtamu B Derseh; Jason Q D Goodger; Jean-Pierre Y Scheerlinck; Chrishan S Samuel; Ian E Woodrow; Enzo A Palombo; Alistair Cumming; Ken Snibson
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

7.  Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis.

Authors:  Louise Organ; Barbara Bacci; Emmanuel Koumoundouros; Garry Barcham; Marjorie Milne; Wayne Kimpton; Chrishan Samuel; Ken Snibson
Journal:  BMC Pulm Med       Date:  2015-07-31       Impact factor: 3.317

8.  KCa3.1 channel blockade attenuates microvascular remodelling in a large animal model of bleomycin-induced pulmonary fibrosis.

Authors:  Habtamu B Derseh; Sasika N Vithana Dewage; Kopiyawaththage U E Perera; Charles N Pagel; Emmanuel Koumoundouros; Louise Organ; Ken J Snibson
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.